Tags

Type your tag names separated by a space and hit enter

A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome.
Intensive Care Med. 2001 Oct; 27(10):1578-83.IC

Abstract

OBJECTIVE

To evaluate the safety of liposomal PGE1 (TLC C-53) in patients with acute respiratory distress syndrome (ARDS), and determine its efficacy in improving oxygenation and reducing ventilator dependency.

DESIGN

A multi-centre, randomized, double-blind, placebo-controlled clinical study.

SETTING

Thirty-one hospitals in six European countries.

PATIENTS

One hundred two patients with ARDS.

INTERVENTIONS

Patients were randomized in a 2:1 ratio to receive infusions of either the study drug TLC C-53 or placebo. Infusions were given over 60 min every 6 h for 7 days. The dose of study drug started at 0.6 microg/kg per h, rising over 24 h to a maximum dose of 1.8 microg/kg per h.

MEASUREMENTS AND MAIN RESULTS

Seventy patients received the study drug and 32 placebo. Sixty-nine patients (47 treatment, 22 placebo) completed the study protocol. Patients were monitored for changes in the PaO2/FIO2 ratio, changes in lung compliance, time to off-ventilator and 28-day mortality, in addition to basic haematological and haemodynamic parameters. There were no significant differences in demographics and baseline characteristics between the two groups. There were no differences in the time to off-ventilation (16 days with treatment, 16.6 days with placebo, p=0.94) or in 28-day mortality (30% with treatment, 28% with placebo, p=0.78). There was a difference in the time to achieve a PaO2/FIO2 ratio above 300 in favour of TLC C-53 (10.3 versus 26.5 days) but this was not statistically significant (p=0.23).

CONCLUSIONS

TLC C-53 was generally well-tolerated but failed to reduce mortality or duration of mechanical ventilation.

Authors+Show Affiliations

Department of Intensive Care, Erasme University Hospital, Route de Lennik 808, 1070 Bruxelles, Belgium. jlvincen@ulb.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

11685297

Citation

Vincent, J L., et al. "A Multi-centre, Double-blind, Placebo-controlled Study of Liposomal Prostaglandin E1 (TLC C-53) in Patients With Acute Respiratory Distress Syndrome." Intensive Care Medicine, vol. 27, no. 10, 2001, pp. 1578-83.
Vincent JL, Brase R, Santman F, et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. 2001;27(10):1578-83.
Vincent, J. L., Brase, R., Santman, F., Suter, P. M., McLuckie, A., Dhainaut, J. F., Park, Y., & Karmel, J. (2001). A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Medicine, 27(10), 1578-83.
Vincent JL, et al. A Multi-centre, Double-blind, Placebo-controlled Study of Liposomal Prostaglandin E1 (TLC C-53) in Patients With Acute Respiratory Distress Syndrome. Intensive Care Med. 2001;27(10):1578-83. PubMed PMID: 11685297.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. AU - Vincent,J L, AU - Brase,R, AU - Santman,F, AU - Suter,P M, AU - McLuckie,A, AU - Dhainaut,J F, AU - Park,Y, AU - Karmel,J, PY - 1999/09/24/received PY - 2001/08/09/accepted PY - 2001/10/31/pubmed PY - 2002/1/15/medline PY - 2001/10/31/entrez SP - 1578 EP - 83 JF - Intensive care medicine JO - Intensive Care Med VL - 27 IS - 10 N2 - OBJECTIVE: To evaluate the safety of liposomal PGE1 (TLC C-53) in patients with acute respiratory distress syndrome (ARDS), and determine its efficacy in improving oxygenation and reducing ventilator dependency. DESIGN: A multi-centre, randomized, double-blind, placebo-controlled clinical study. SETTING: Thirty-one hospitals in six European countries. PATIENTS: One hundred two patients with ARDS. INTERVENTIONS: Patients were randomized in a 2:1 ratio to receive infusions of either the study drug TLC C-53 or placebo. Infusions were given over 60 min every 6 h for 7 days. The dose of study drug started at 0.6 microg/kg per h, rising over 24 h to a maximum dose of 1.8 microg/kg per h. MEASUREMENTS AND MAIN RESULTS: Seventy patients received the study drug and 32 placebo. Sixty-nine patients (47 treatment, 22 placebo) completed the study protocol. Patients were monitored for changes in the PaO2/FIO2 ratio, changes in lung compliance, time to off-ventilator and 28-day mortality, in addition to basic haematological and haemodynamic parameters. There were no significant differences in demographics and baseline characteristics between the two groups. There were no differences in the time to off-ventilation (16 days with treatment, 16.6 days with placebo, p=0.94) or in 28-day mortality (30% with treatment, 28% with placebo, p=0.78). There was a difference in the time to achieve a PaO2/FIO2 ratio above 300 in favour of TLC C-53 (10.3 versus 26.5 days) but this was not statistically significant (p=0.23). CONCLUSIONS: TLC C-53 was generally well-tolerated but failed to reduce mortality or duration of mechanical ventilation. SN - 0342-4642 UR - https://www.unboundmedicine.com/medline/citation/11685297/A_multi_centre_double_blind_placebo_controlled_study_of_liposomal_prostaglandin_E1__TLC_C_53__in_patients_with_acute_respiratory_distress_syndrome_ L2 - https://dx.doi.org/10.1007/s001340101077 DB - PRIME DP - Unbound Medicine ER -